先端巨大症治療市場規模、シェア、成長分析：疾患タイプ別、診断タイプ別、治療タイプ別、地域別 - 産業予測 2025～2032年

先端巨大症治療の世界市場規模は2023年に14億米ドルと評価され、2024年の14億9,000万米ドルから2032年には23億9,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは6.1％で成長する見通しです。

先端巨大症治療市場は、罹患率の上昇と革新的な治療法に対する需要の高まりにより、力強い成長が見込まれています。研究開発投資の急増に伴い、製薬企業は新しい製剤や投与方法の創出に注力しています。遺伝性疾患の蔓延やライフスタイルの変化は、特にホルモン障害が一般的になるにつれて、この需要に拍車をかけると予想されます。特に、新しい成長ホルモン受容体拮抗薬やソマトスタチン類似薬のFDA承認が期待されるなど、強力な薬学的パイプラインが市場の可能性をさらに高めると思われます。放射線手術のような検出方法の技術的進歩は、治療効果を高め、副作用を軽減します。さらに、希少疾患に対する政府の支援政策やプログラムは、今後数年間の市場拡大に寄与すると思われます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

先端巨大症治療市場規模：疾患タイプ別

• 市場概要
• 異所性先端巨大症
• 偽性先端巨大症

先端巨大症治療市場規模：診断タイプ別

• 市場概要
• 医療画像
• 臨床検査

先端巨大症治療市場規模：治療タイプ別

• 市場概要
• 手術
• 薬物療法
• 放射線治療

先端巨大症治療市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• Novartis AG（Switzerland）
• Ipsen Pharma（France）
• Pfizer Inc.（USA）
• Crinetics Pharmaceuticals, Inc.（USA）
• Strongbridge Biopharma plc（Ireland）
• Ionis Pharmaceuticals, Inc.（USA）
• Merck & Co., Inc.（USA）
• AbbVie Inc.（USA）
• Eli Lilly and Company（USA）
• AstraZeneca PLC（UK）
• Sanofi S.A.（France）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Hikma Pharmaceuticals PLC（UK）
• Lupin Ltd.（India）
• Recordati S.p.A.（Italy）
• Xeris Biopharma Holdings, Inc.（USA）
• Peptron Inc.（South Korea）

結論と推奨事項

Global Acromegaly Treatment Market size was valued at USD 1.4 billion in 2023 and is poised to grow from USD 1.49 billion in 2024 to USD 2.39 billion by 2032, growing at a CAGR of 6.1% during the forecast period (2025-2032).

The acromegaly treatment market is poised for robust growth, driven by the rising incidence of the disease and the increasing demand for innovative therapies. With a surge in research and development investments, pharmaceutical companies are focused on creating new drug formulations and administration methods. The prevalence of hereditary conditions and lifestyle changes is expected to fuel this demand, especially as hormonal disorders become more common. Notably, a strong pharmacological pipeline, including anticipated FDA approvals for new growth hormone receptor antagonists and somatostatin analogues, will further elevate market potential. Technological advancements in detection methods like radiosurgery are set to enhance treatment efficacy and reduce side effects. Additionally, supportive government policies and programs for rare diseases will contribute to market expansion in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Acromegaly Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Acromegaly Treatment Market Segmental Analysis

Global Acromegaly Treatment Market is segmented by Disease Type, Diagnosis Type, Treatment Type and region. Based on Disease Type, the market is segmented into Ectopic Acromegaly and Pseudo Acromegaly. Based on Diagnosis Type, the market is segmented into Medical Imaging and Medical Laboratory Test. Based on Treatment Type, the market is segmented into Surgery, Drug Therapy and Radiation Therapy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Acromegaly Treatment Market

The acromegaly treatment market is predominantly driven by the rising incidence of acromegaly, a rare endocrine disorder characterized by an overproduction of growth hormone. As awareness surrounding the condition increases and diagnostic capabilities enhance, more individuals are being identified and treated for acromegaly. This growing recognition of the disease correlates with heightened demand for effective therapeutic solutions, stimulating advancements in treatment options. Consequently, the escalating prevalence of acromegaly significantly propels the market forward, creating opportunities for pharmaceutical companies to innovate and expand their offerings in this specialized healthcare sector as patient needs evolve.

Restraints in the Global Acromegaly Treatment Market

The Global Acromegaly Treatment market faces significant restraints, primarily due to limited awareness and underdiagnosis of the condition. Although acromegaly is becoming more prevalent, many cases remain undetected or are diagnosed later than ideal because the symptoms develop gradually and are often non-specific. This lack of awareness among healthcare professionals and the general public contributes to delays in diagnosis and treatment, ultimately hindering the growth of the market. Addressing these awareness gaps is crucial for facilitating early detection and improving patient outcomes in acromegaly treatment.

Market Trends of the Global Acromegaly Treatment Market

The Global Acromegaly Treatment market is increasingly trending towards targeted therapies, significantly reshaping treatment approaches. This shift is characterized by the rising adoption of somatostatin analogs and growth hormone receptor antagonists, which adeptly address the underlying hormonal imbalances that contribute to acromegaly. By providing enhanced efficacy and improved tolerability compared to traditional treatments, these innovative therapies cater to the growing demand for personalized medicine. As awareness and diagnosis rates of acromegaly rise, coupled with advancements in pharmaceutical research, the market is projected to expand, driven by the continued development and commercialization of these specialized treatment options.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Acromegaly Treatment Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Ectopic Acromegaly
• Pseudo Acromegaly

Global Acromegaly Treatment Market Size by Diagnosis Type & CAGR (2025-2032)

• Market Overview
• Medical Imaging
• Medical Laboratory Test

Global Acromegaly Treatment Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Surgery
• Drug Therapy
• Radiation Therapy

Global Acromegaly Treatment Market Size & CAGR (2025-2032)

• North America (Disease Type, Diagnosis Type, Treatment Type)
  • US
  • Canada
• Europe (Disease Type, Diagnosis Type, Treatment Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Diagnosis Type, Treatment Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Diagnosis Type, Treatment Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Diagnosis Type, Treatment Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Crinetics Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Strongbridge Biopharma plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recordati S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Xeris Biopharma Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Peptron Inc. (South Korea
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations